| Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy WF Symmans, F Peintinger, C Hatzis, R Rajan, H Kuerer, V Valero, ... Journal of Clinical Oncology 25 (28), 4414-4422, 2007 | 1966 | 2007 |
| The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models Nature biotechnology 28 (8), 827-838, 2010 | 939 | 2010 |
| Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype WF Symmans, C Wei, R Gould, X Yu, Y Zhang, M Liu, A Walls, ... Journal of Clinical Oncology 35 (10), 1049-1060, 2017 | 785 | 2017 |
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 749 | 2011 |
| Common contaminants in next-generation sequencing that hinder discovery of low-abundance microbes M Laurence, C Hatzis, DE Brash PloS one 9 (5), e97876, 2014 | 373 | 2014 |
| Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry T Iwamoto, D Booser, V Valero, JL Murray, K Koenig, FJ Esteva, NT Ueno, ... Journal of Clinical Oncology 30 (7), 729-734, 2012 | 356 | 2012 |
| Multigene prognostic tests in breast cancer: past, present, future B Győrffy, C Hatzis, T Sanft, E Hofstatter, B Aktas, L Pusztai Breast cancer research 17 (1), 11, 2015 | 349 | 2015 |
| Commercialized multigene predictors of clinical outcome for breast cancer JS Ross, C Hatzis, WF Symmans, L Pusztai, GN Hortobágyi The Oncologist 13 (5), 477-493, 2008 | 332 | 2008 |
| Genomic index of sensitivity to endocrine therapy for breast cancer WF Symmans, C Hatzis, C Sotiriou, F Andre, F Peintinger, P Regitnig, ... Journal of clinical oncology 28 (27), 4111-4119, 2010 | 306 | 2010 |
| Effect of training-sample size and classification difficulty on the accuracy of genomic predictors V Popovici, W Chen, BD Gallas, C Hatzis, W Shi, FW Samuelson, ... Breast Cancer Research 12 (1), R5, 2010 | 263 | 2010 |
| Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor–positive and–negative cancers G Bianchini, Y Qi, RH Alvarez, T Iwamoto, C Coutant, NK Ibrahim, ... Journal of Clinical Oncology 28 (28), 4316-4323, 2010 | 243 | 2010 |
| Genomic grade index is associated with response to chemotherapy in patients with breast cancer C Liedtke, C Hatzis, WF Symmans, C Desmedt, B Haibe-Kains, V Valero, ... Journal of clinical oncology 27 (19), 3185-3191, 2009 | 232 | 2009 |
| Association between genomic metrics and immune infiltration in triple-negative breast cancer T Karn, T Jiang, C Hatzis, N Sänger, A El-Balat, A Rody, U Holtrich, ... JAMA oncology 3 (12), 1707-1711, 2017 | 173 | 2017 |
| KDD Cup 2001 report J Cheng, C Hatzis, H Hayashi, MA Krogel, S Morishita, D Page, J Sese ACM SIGKDD Explorations Newsletter 3 (2), 47-64, 2002 | 169 | 2002 |
| Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor–positive breast cancer F Andre, C Hatzis, K Anderson, C Sotiriou, C Mazouni, J Mejia, B Wang, ... Clinical cancer research 13 (7), 2061-2067, 2007 | 164 | 2007 |
| Hydrolysis and fractionation of lignocellulosic biomass RW Torget, N Padukone, C Hatzis, CE Wyman US Patent 6,022,419, 2000 | 157 | 2000 |
| Immune gene expression is associated with genomic aberrations in breast cancer A Safonov, T Jiang, G Bianchini, B Győrffy, T Karn, C Hatzis, L Pusztai Cancer research 77 (12), 3317-3324, 2017 | 156 | 2017 |
| Identification of inhibitory components toxic toward Zymomonas mobilis CP4 (pZB5) xylose fermentation TD Ranatunga, J Jervis, RF Helm, JD McMillan, C Hatzis Applied biochemistry and biotechnology 67 (3), 185-198, 1997 | 155 | 1997 |
| Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy F Peintinger, B Sinn, C Hatzis, C Albarracin, E Downs-Kelly, J Morkowski, ... Modern Pathology 28 (7), 913-920, 2015 | 143 | 2015 |
| A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients L Pongor, M Kormos, C Hatzis, L Pusztai, A Szabó, B Győrffy Genome medicine 7 (1), 104, 2015 | 141 | 2015 |
William Fraser SymmansProfessor of Pathology, University of Texas MD Anderson Cancer CenterVerified email at mdanderson.org
